A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis
Latest Information Update: 06 Nov 2021
At a glance
- Drugs ARI 3037MO (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Arisaph Pharmaceuticals
Most Recent Events
- 05 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Oct 2015 New trial record